
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetic Laboratories, discusses Prolaris testing in men who have clinically localized prostate cancer.
Brawer describes how the Prolaris test helps to provide prognostic information in men with this disease. It determines who needs aggressive therapy from those who can handle conservative treatment and still do well.
Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetic Laboratories, discusses Prolaris testing in men who have clinically localized prostate cancer.






